Related Experiment Video
Updated: Jun 4, 2026
Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011
Ultrasensitive Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma by the AMPLICOR and COBAS AMPLICOR
S Herman1, J Novotny, M Rosenstraus
1Roche Molecular Systems, Alameda, CA.
Abstract:
The measurement of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels has become an important tool for identifying individuals likely to benefit from antiretroviral therapy (1-7) as well as monitoring patients on therapy (8-14), and is now regarded as standard medical practice for managing the treatment of HIV-1-infected individuals (15-21). Three commercially available assays for measuring HIV-1 RNA levels are available. The firstgeneration AMPLICOR HIV-1 MONITOR™ Test, which uses reverse transcriptase-polymerase chain reaction (RT-PCR) technology, has a lower limit of quantitation of 400 copies/mL of plasma (22,23). The NucliSens HIV-1 QT Test (Organon Teknika, Boxtel, Netherlands), a second-generation assay based on the nucleic acid sequence-based amplification technique, has a lower limit of quantitation of 100 HIV-1 RNA copies/mL of plasma (24). The Quantiplex HIV-1 Version 2.0 Test (Chiron, Emeryville, CA), which uses the branched-chain DNA signal amplification technique, has a lower limit of quantitation of 500 HIV-1 RNA copies/mL of plasma (25,26).
